Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
RegeneRx Biopharmaceuticals Inc. Stock Analysis RGRX
United States Health Care Nano Cap RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. The company is headquartered in Glen Echo, Maryland and currently employs 2 full-time employees. The firm has formulated TB4 into three distinct product candidates in clinical development: RGN-259, RGN-352 and RGN-137. RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-259 is in phase three clinical trials in the United States and EU for the treatment of neurotrophic keratitis, an orphan indication. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, organ damage associated with COVID-19, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. The company has active partnerships in four territories: North America, Europe, China and Pan Asia.
Read More RegeneRx Biopharmaceuticals Inc (RGRX) Chart
Key Statistics of RegeneRx Biopharmaceuticals Inc (RGRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
235.00P/E Ratio (TTM)
-52 Week Range
Market Cap
748.00Avg. Volume
173.67Dividend Yield
-Financial Metrics & Statements of RegeneRx Biopharmaceuticals Inc (RGRX)
FAQ's for RegeneRx Biopharmaceuticals Inc (RGRX)
- According to Musaffa’s Shariah screening methodology, RegeneRx Biopharmaceuticals Inc (RGRX) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes RegeneRx Biopharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in RegeneRx Biopharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of RegeneRx Biopharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of RegeneRx Biopharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of RegeneRx Biopharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.